Potential risks of poorly monitored ketamine use in depression treatment

American Journal of Psychiatry

Volumn 173, Issue 3, 2016, Pages 215-218

  Schak, Kathryn M ^a   Voort, Jennifer L Vande ^a   Johnson, Emily K ^a   Kung, Simon ^a   Leung, Jonathan G ^a   Rasmussen, Keith G ^a   Palmer, Brian A ^a   Frye, Mark A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONAZEPAM; ESZOPICLONE; KETAMINE; LITHIUM SALT; LORAZEPAM; MIRTAZAPINE; TETRAHYDROCANNABINOL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT;

ADULT; ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; AUTOPSY; CASE REPORT; DEATH; DEPRESSION; DRINKING BEHAVIOR; DRUG MISUSE; DRUG MONITORING; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG USE; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE DRUG DOSE; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TRAFFIC ACCIDENT; ALCOHOL-RELATED DISORDERS; CLINICAL PRACTICE; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; MIDDLE AGED; PROCEDURES; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGY; SUBSTANCE ABUSE; SUBSTANCE-RELATED DISORDERS;

ALCOHOL-RELATED DISORDERS; ANALGESICS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSIS, DUAL (PSYCHIATRY); ELECTROCONVULSIVE THERAPY; HUMANS; KETAMINE; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; RISK ASSESSMENT; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; SUICIDE;

EID: 84959535419     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15081082     Document Type: Note

References (15)

1. Li X, Frye MA, Shelton RC: Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology 2012;37:77-101
2. Newport DJ, Carpenter LL, McDonald WM, et al: Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172:950-966
3. Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 2015;40:1307
4. Bokor G, Anderson PD: Ketamine: an update on its abuse. J Pharm Pract 2014;27:582-586
5. Lindefors N, Barati S, O'Connor WT: Differential effects of single and repeated ketamine administration on dopamine, serotonin, and GABA transmission in rat medial prefrontal cortex. Brain Res 1997;759:205-212
6. Xu K, Lipsky RH: Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implicationof genetic vulnerability for ketamine abuse and ketamine psychosis in humans. Exp Biol Med (Maywood) 2015;240:145-155
7. Andrade C: Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. J Clin Psychiatry 2015;76:628-631
8. Clark P: Treatment-refractory depression: a case of successful treatment with intranasal ketamine 10%. Ann Clin Psychiatry 2014;26:145
9. Stockwell T, Donath S, Cooper-Stanbury M, et al: Under-reporting of alcohol consumptionin household surveys: a comparisonof quantityfrequency, graduated-frequency, and recent recall. Addiction 2004;99:1024-1033
10. Kessler RC, Crum RM, Warner LA, et al: Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry 1997;54:313-321
11. Pettinati HM, Oslin DW, Kampman KM, et al: A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010;167:668-675
12. Dickey B, Dembling B, Azeni H, et al: Externally caused deaths for adults with substance use and mental disorders. J Behav Health Serv Res 2004;31:75-85
13. Wittich CM, Burkle CM, Lanier WL: Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012;87:982-990
14. Liu JX, Zerbo E, Ross S: Intensive ketamine use for multiple years: a case report. Am J Addict 2015;24:7-9
15. Schatzberg AF: A word to the wise about ketamine. Am J Psychiatry 2014;171:262-264